100
5 key milestones in FDA-approved digital therapeutics
FDA approved 50% more Digital Therapeutics (DTx) in 2023 compared to 2022.
Nerivio is a wearable device for migraine treatment, utilizing remote electrical neuromodulation.
Lenire received FDA De Novo approval as a pioneering tinnitus treatment device.
Somryst is the first FDA-approved DTx for chronic insomnia.
ReSET and ReSET-O are FDA-cleared DTx for substance use disorders.
Save this answer
Create your account to keep this answer and continue from it later.
Sorry, Pandi could not find an answer.
Let's look at alternatives:
- Modify the query.
- Start a new thread.
- Remove sources (if manually added).
Related Content From The Pandipedia
5 key milestones in senolytic drug developmentFDA cleared AI medical devices listEvolution of Sleep Monitoring Technology: From Polysomnography to Smart Rings and BeyondCultural Variations in HumorA pocket history of the digital detox movementCan wearables predict migraine onset using multisensor data?How do wearable sleep trackers help personalize recovery protocols for seniors?Navigating FDA Clearance for AI‐Enabled Wearables: Regulatory Pathways, Clinical Evidence, and Post‐Market SurveillanceWhat year did Apple introduce the Screen Time feature?updated guidelines on medical AI device approvalsExtended Reality in Digital Therapeutics for Mental Health Care5 milestones in holographic display techUnderstanding the Neuroscience Behind Constant Notification Sound ExposureWhat is a carrot? Quantum Computing in Pharmaceutical R&D: Transforming Drug Discovery over the Next Decade